Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
55 hedge funds and large institutions have $24.2M invested in Orexigen Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% less funds holding
Funds holding: 73 → 55 (-18)
31% less capital invested
Capital invested by funds: $35.1M → $24.2M (-$10.9M)
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
61% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 28
68% less call options, than puts
Call options by funds: $229K | Put options by funds: $706K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.26M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$997K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$792K |
| 4 |
Morgan Stanley
New York
|
+$199K |
| 5 |
PP
PDT Partners
New York
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$4.26M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$349K |
| 3 |
DY
Dowling & Yahnke
San Diego,
California
|
-$294K |
| 4 |
Renaissance Technologies
New York
|
-$236K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$231K |
OREX Hedge Fund Activity: Q3 2016 in Review
55 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q3 2016, worth a combined $24.2M — down 31% from $35.1M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of OREX and 11 opened new positions — a net loss of 17 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was NEA Management Company, adding an estimated $1.26M. The largest seller was Tiverton Asset Management, exiting entirely with an estimated $4.26M sold.
- 55 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q3 2016, down from 73 in Q2 2016.
- Funds reported $24.2M of Orexigen Therapeutics, Inc. stock for Q3 2016, down 31% quarter-over-quarter.
- 11 funds opened new Orexigen Therapeutics, Inc. positions in Q3 2016 and 28 closed out, a net change of -17 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q3 2016 was NEA Management Company, an estimated $1.26M added.
- The largest Orexigen Therapeutics, Inc. seller in Q3 2016 was Tiverton Asset Management, an estimated $4.26M sold.
Based on aggregated 13F filings for Q3 2016.